Scandion Oncology A/S (SCOL) - Cash Flow Conversion Efficiency

Latest as of December 2024: -0.220x

Based on the latest financial reports, Scandion Oncology A/S (SCOL) has a cash flow conversion efficiency ratio of -0.220x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.82 Million ≈ $-195.65K USD) by net assets (Skr8.27 Million ≈ $889.77K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Scandion Oncology A/S - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Scandion Oncology A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Scandion Oncology A/S balance sheet liabilities for a breakdown of total debt and financial obligations.

Scandion Oncology A/S Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scandion Oncology A/S ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Rockfire Resources plc LSE:ROCK	-0.092x
Pennant International Group plc LSE:PEN	-0.134x
Taptica International Ltd LSE:TAP	0.065x
Stora Enso Oyj ser. R ST:STE-R	0.015x
Tower Resources plc LSE:TRP	-0.051x
Conroy Gold & Natural Resources Plc LSE:CGNR	-0.028x
Titon Holdings Plc LSE:TON	0.094x
Gresham House Renewable Energy VCT 1 plc LSE:GV1O	0.003x

Annual Cash Flow Conversion Efficiency for Scandion Oncology A/S (2017–2024)

The table below shows the annual cash flow conversion efficiency of Scandion Oncology A/S from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see SCOL market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr8.27 Million ≈ $889.77K	Skr-27.52 Million ≈ $-2.96 Million	-3.328x	-104.45%
2023-12-31	Skr31.12 Million ≈ $3.35 Million	Skr-50.67 Million ≈ $-5.45 Million	-1.628x	-64.88%
2022-12-31	Skr70.33 Million ≈ $7.57 Million	Skr-69.44 Million ≈ $-7.47 Million	-0.987x	-107.29%
2021-12-31	Skr104.54 Million ≈ $11.25 Million	Skr-49.80 Million ≈ $-5.36 Million	-0.476x	-325.45%
2020-12-31	Skr155.87 Million ≈ $16.77 Million	Skr-17.45 Million ≈ $-1.88 Million	-0.112x	+79.38%
2019-12-31	Skr18.34 Million ≈ $1.97 Million	Skr-9.96 Million ≈ $-1.07 Million	-0.543x	+48.59%
2018-12-31	Skr12.57 Million ≈ $1.35 Million	Skr-13.28 Million ≈ $-1.43 Million	-1.056x	-28.93%
2017-12-31	Skr1.45 Million ≈ $156.34K	Skr-1.19 Million ≈ $-128.07K	-0.819x	--

About Scandion Oncology A/S

ST:SCOL Sweden Biotechnology

Market Cap

$103.58K

Skr962.52K SEK

Market Cap Rank

#30976 Global

#741 in Sweden

Share Price

Skr0.00

Change (1 day)

-39.71%

52-Week Range

Skr0.00 - Skr0.03

All Time High

Skr22.90